Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R21 Clinical Trial Not Allowed) | RFA DE 22 004

FAQs: NIH RFA-DE-22-004 (R21) Oral HPV in People Living with HIV

What is this funding opportunity (RFA-DE-22-004) about?

This NIH funding opportunity supports exploratory, early-stage research to improve what is known about oral human papillomavirus (HPV) infection in people living with HIV. It is focused on how oral HPV is acquired, how and why it persists over time, and the underlying biology of oral HPV specifically in the setting of HIV.

What are the main scientific questions this opportunity wants to address?

The announcement emphasizes foundational questions, including: how oral HPV is acquired in people living with HIV; what factors shape persistence versus clearance over time; what host-virus and immune-related biological mechanisms are involved; and what early mechanisms may connect oral HPV infection to later development of HPV-associated oral and oropharyngeal cancers and HPV-related oral warts, particularly considering HIV-related immune changes.

Why is the focus specifically on people living with HIV?

The opportunity is centered on people living with HIV because HIV-related immune changes may alter oral HPV risk, persistence, and disease progression compared with HIV-negative populations. The goal is to clarify how oral HPV behaves under HIV-associated immune conditions.

What diseases or outcomes are highlighted as long-term concerns?

The opportunity highlights HPV-associated oral and oropharyngeal cancers and HPV-related oral warts. A major emphasis is understanding the earliest mechanisms that may link oral HPV infection to these later outcomes.

Is this opportunity aimed at basic science, epidemiology, or both?

Both. The solicitation is positioned as foundational and seeks to strengthen the evidence base around (1) epidemiology, including who gets oral HPV, under what conditions, and how infection patterns change over time, and (2) biological processes, including host-virus interactions, immune factors, and other mechanistic pathways that shape acquisition and persistence.

What does it mean that this is an R21 mechanism?

The funding mechanism is an R21, which is typically used for exploratory and early-stage projects. The expectation described here is that studies should be innovative and hypothesis-generating, produce preliminary data, or test emerging ideas that could later support larger, more definitive projects.

Are clinical trials allowed under this funding opportunity?

No. The notice explicitly states that clinical trials are not allowed. Applicants should design studies that do not meet the definition of a clinical trial.

What kind of study designs would be problematic because clinical trials are not allowed?

According to the information provided, designs would be problematic if they prospectively assign human participants to an intervention in order to evaluate the effects of that intervention on health-related outcomes. The key issue is prospective assignment to an intervention with evaluation of health outcomes.

What kinds of projects seem to fit the intent of this announcement?

Projects that build foundational knowledge about oral HPV in people living with HIV, including work that clarifies acquisition, persistence, epidemiologic patterns over time, and underlying biology and immune mechanisms. The intent is to generate evidence and early insights that can later support prevention, risk stratification, and future intervention development (even though the R21-funded work here cannot itself be a clinical trial).

What is the broader goal of the funded research?

The overall goal is to sharpen understanding of why oral HPV behaves the way it does in people living with HIV and to illuminate early pathways that may set the stage for HPV-related oral and oropharyngeal malignancies and oral warts.

Who is the funder and what type of grant is this?

This is a discretionary grant opportunity from the National Institutes of Health (NIH), categorized under education and health-related funding activities.

What are the CFDA numbers associated with this opportunity?

The opportunity is associated with CFDA 93.121 and several 93.39x listings: 93.393, 93.394, 93.395, 93.396, and 93.399.

When was this opportunity created, and what was the listed closing date?

The opportunity was created on June 28, 2021. The original closing date listed for applications was November 18, 2021.

Does the provided information include an award ceiling or the expected number of awards?

No. The source information provided does not specify an award ceiling or the expected number of awards.

Where would an applicant typically look for budget guidance or project period limits?

Based on the information provided, applicants would typically look to the full funding announcement or NIH notices for budget guidance, project period limits, and institute-specific priorities.

What types of organizations are eligible to apply?

Eligibility is broad and includes many organization types across government, academia, nonprofit, and industry. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; and other entities described in the announcement.

Are tribal governments or tribal organizations eligible?

Yes. Eligible applicants include Native American tribal governments (federally recognized) and Native American tribal organizations that are not federally recognized governments.

Are nonprofits eligible, and does 501(c)(3) status matter?

Yes. The announcement includes nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status, with the stated exclusion that these nonprofit categories exclude institutions of higher education as described.

Are for-profit organizations and small businesses eligible?

Yes. Eligible applicants include for-profit organizations other than small businesses, as well as small businesses.

Are housing authorities eligible to apply?

Yes. The eligible applicants list includes public housing authorities and Indian housing authorities.

Are minority-serving institutions specifically encouraged or listed as eligible?

Yes. The announcement highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); and Tribally Controlled Colleges and Universities (TCCUs).

Are faith-based or community-based organizations eligible?

Yes. The announcement explicitly lists faith-based or community-based organizations among additional eligible applicants.

Are U.S. territories or possessions eligible?

Yes. The announcement lists U.S. territories or possessions as eligible.

Are non-U.S. (foreign) organizations eligible to apply?

Yes. The announcement states that non-U.S. (foreign) organizations are eligible.

Are federal agencies eligible applicants?

Yes. The announcement includes eligible federal agencies among additional eligible applicants.

What kinds of expertise or teams does this opportunity seem designed for?

In practical terms, it is designed for teams that can bring together expertise in HIV, virology, oral health, cancer biology, immunology, epidemiology, and related behavioral or social determinants that might influence oral HPV transmission and persistence.

What role do behavioral or social determinants play in the scope described?

The opportunity notes that related behavioral or social determinants may influence oral HPV transmission and persistence, and it suggests that such factors may be relevant within the broader research scope.

How does the opportunity describe the expected impact of the work?

The work is described as foundational, intended to strengthen the evidence base around epidemiology and biological mechanisms of oral HPV in people living with HIV. The longer-term intent is to support better prevention, risk stratification, and future intervention development, while staying within the constraint that the funded studies cannot be clinical trials.